Literature DB >> 15010998

[Therapy-related changes of angiogenesis in Philadelphia chromosome positive chronic myelogenous leukemia].

H M Kvasnicka1, J Thiele, P Staib, K Engels, S Kriener, A Schmitt-Graeff.   

Abstract

To elucidate the effect of first-line treatment with interferon (IFN), hydroxyurea (HU) and the tyrosine kinase inhibitor imatinib (STI571) on angiogenesis, we studied bone marrow (BM) biopsies in 104 patients with chronic myelogenous leukemia (CML) and 138 patients before and after allogeneic BM transplantation (BMT). After immunostaining (CD34) and morphometric analysis in comparison with a control group, CML specimens showed an increased vascularity and conspicuous morphological abnormalities of microvessels. A close relationship between microvessels and fiber density was detectable in initial biopsies and also in repeatedly performed examinations following therapy. Monotherapy by imatinib and HU generated a significant reduction of microvessels and reticulin fibers in contrast to changes after IFN administration or combination regimens of IFN and HU. A persistence of numerical and structural anomalies of vasculature was observable even several months after BMT. These anomalies shed some light on disturbances of the stroma compartment after myeloablative therapy. The relationship between BM vascularity and fibers is probably dependent on concomitant changes of megakaryopoiesis as the source of various mediators involved in the development of myelofibrosis and neo-angiogenesis acting within a complex functional network.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15010998     DOI: 10.1007/s00292-003-0677-y

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  63 in total

1.  Tumour vascularity and proliferation: clear evidence of a close relationship.

Authors:  N Weidner
Journal:  J Pathol       Date:  1999-11       Impact factor: 7.996

2.  Megakaryocytes and sinus walls in primary osteomyelofibrosis: transendothelial migration as revealed by three-dimensional reconstruction of serial sections following sequential double-immunostaining.

Authors:  J Thiele; H M Kvasnicka; T Amend; R Fischer
Journal:  Virchows Arch       Date:  1994       Impact factor: 4.064

3.  A requirement for Flk1 in primitive and definitive hematopoiesis and vasculogenesis.

Authors:  F Shalaby; J Ho; W L Stanford; K D Fischer; A C Schuh; L Schwartz; A Bernstein; J Rossant
Journal:  Cell       Date:  1997-06-13       Impact factor: 41.582

4.  Hypoxia augments cytokine (transforming growth factor-beta (TGF-beta) and IL-1)-induced vascular endothelial growth factor secretion by human synovial fibroblasts.

Authors:  B Berse; J A Hunt; R J Diegel; P Morganelli; K Yeo; F Brown; R A Fava
Journal:  Clin Exp Immunol       Date:  1999-01       Impact factor: 4.330

5.  Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors.

Authors:  M Peichev; A J Naiyer; D Pereira; Z Zhu; W J Lane; M Williams; M C Oz; D J Hicklin; L Witte; M A Moore; S Rafii
Journal:  Blood       Date:  2000-02-01       Impact factor: 22.113

6.  In vitro differentiation of endothelial cells from AC133-positive progenitor cells.

Authors:  U M Gehling; S Ergün; U Schumacher; C Wagener; K Pantel; M Otte; G Schuch; P Schafhausen; T Mende; N Kilic; K Kluge; B Schäfer; D K Hossfeld; W Fiedler
Journal:  Blood       Date:  2000-05-15       Impact factor: 22.113

7.  [Histologic and hematological findings in CML. A comparative immunohistochemical-morphometric and clinical study on bone marrow biopsies from 604 patients derived from two institutes of pathology (Cologne/Freiburg)].

Authors:  J Thiele; H M Kvasnicka; A Schmitt-Graeff; H E Schaefer
Journal:  Pathologe       Date:  2000-01       Impact factor: 1.011

Review 8.  Angiogenesis in chronic myeloproliferative diseases.

Authors:  F Di Raimondo; G A Palumbo; S Molica; R Giustolisi
Journal:  Acta Haematol       Date:  2001       Impact factor: 2.195

9.  Bone marrow stromal cell distribution of basic fibroblast growth factor in chronic myeloid disorders.

Authors:  S Y Yoon; A Tefferi; C Y Li
Journal:  Haematologica       Date:  2001-01       Impact factor: 9.941

10.  BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1alpha, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin.

Authors:  Matthias Mayerhofer; Peter Valent; Wolfgang R Sperr; James D Griffin; Christian Sillaber
Journal:  Blood       Date:  2002-07-18       Impact factor: 22.113

View more
  1 in total

1.  [Hematological side effects of tyrosine kinase inhibition using imatinib].

Authors:  A Schmitt-Graeff; A Hochhaus
Journal:  Pathologe       Date:  2006-02       Impact factor: 1.011

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.